Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 7Active not recruiting 5Completed 2Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Myelodysplastic Syndromes 1

Interventions

Specimen Handling 3venetoclax 2Biopsy 2vactosertib 1regorafenib 1iadademstat 1fludarabine phosphate 1fludarabine 1eltrombopag 1decitabine and cedazuridine drug combination 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1X-Rays 1TAK-243 1Photons 1Melphalan 1KB004 1Interleukin-2 1IL32 protein, human 1Genetic Testing 1Cyclophosphamide 1CYC065 1CA-4948 1Azacitidine 1Ascorbic Acid 1Actinium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × X-Rays × Myeloid × Clear all
NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

National Cancer Institute (NCI)

Phase 1 Suspended
30 enrolled
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡